CTOs on the Move

Assisted Living Concepts

www.alcco.com

 
Assisted Living Concepts, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Assisted Living Concepts, Inc. is based in Menomonee Falls, WI. You can find more information on Assisted Living Concepts, Inc. at www.alcco.com
  • Number of Employees: 5K-10K
  • Annual Revenue: $100-250 Million
  • www.alcco.com
  • w140 Lilly Rd N 8981
    Menomonee Falls, WI USA 53051
  • Phone: 262.257.8888

Executives

Name Title Contact Details

Similar Companies

Theragenics Corporation

Theragenics Corporation is a medical device company serving the surgical products and cancer treatment markets. The Company operates in two segments: brachytherapy seed business and the surgical products business. In the brachytherapy seed business, the

EcoNugenics

EcoNugenics® was founded in 1995 by Dr. Isaac Eliaz, M.D., M.S., L.Ac. - a pioneer and expert in the field of integrative medicine, and a highly regarded clinical practitioner, formulator, researcher and author. Dr. Eliaz leads our research activities in natural, integrative approaches to cellular, immune, metabolic, digestive, and cardiovascular health, as well as detoxification.

Ambulatory Surgical Centres Canada Corporation

Ambulatory Surgical Centres Canada Corporation is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atlas Lift Tech

ATLAS Lift Tech is transforming the way care delivery organizations nati​onwide deploy and manage safe patient handling and mobility (SPHM) programs.

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.